A patient with advanced intrahepatic cholangiocarcinoma benefited from personalized neoantigen peptide immunotherapy, demonstrating the potential of tumor-specific peptide vaccines for rare cancers.
Personalized for rare cancerNeoantigen peptide vaccine designed from individual tumor mutations showed clinical benefit in a cancer type with few treatment options
What the researchers found
Personalized neoantigen peptide immunotherapy induced tumor-specific immune responses and clinical benefit in a patient with advanced intrahepatic cholangiocarcinoma.
Why it matters
Rare cancers like cholangiocarcinoma are often excluded from clinical trials. Personalized neoantigen vaccines offer a treatment approach that works for any cancer type, potentially transforming care for rare cancer patients.
The numbers in context
Overall survival for advanced ICC is less than 1 year with standard treatments; this patient showed benefit from personalized immunotherapy.
How the study worked
Case report: whole exome sequencing to identify tumor neoantigens, peptide vaccine design, immunotherapy administration, and assessment of immune responses and clinical outcomes.
Who was studied
Single patient with advanced intrahepatic cholangiocarcinoma
What this study cannot tell us
Single case report — the weakest form of evidence. Response may not be generalizable. Manufacturing individual neoantigen vaccines is time-consuming and expensive.
How to read the evidence
Preliminary evidence: single case report demonstrating feasibility and clinical benefit. Larger trials needed.
When this study was published
Published in 2024. Among the first applications of neoantigen immunotherapy to cholangiocarcinoma.
The bigger picture
Personalized cancer vaccines are moving from laboratory concept to clinical reality. This case demonstrates their applicability to rare cancers that are underserved by standard treatment, suggesting that tumor-specific peptide vaccines could eventually be available for any patient regardless of cancer type.
Questions still open
- Would neoantigen vaccination benefit other cholangiocarcinoma patients in a clinical trial?
- Can the manufacturing timeline be shortened to treat patients with rapidly progressing disease?
- How does personalized neoantigen therapy compare to standard chemotherapy for cholangiocarcinoma?
Common questions
Can a vaccine be made specifically for my cancer?
Is this available as a treatment now?
Read the original research
An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.
Inflammation, 47(5), 1699-1705
Citation
Zhu, Sihui; Liu, Chenxi; Jin, Yunchen; Zhang, Hailong; Zhou, Mingzhen; Xu, Chen; Shao, Jie; Liu, Qin; Wei, Jia; Shen, Jie; Liu, Baorui. (2024). An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.. Inflammation, 47(5), 1699-1705. https://doi.org/10.1007/s10753-024-02003-8